Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors

Checkpoint inhibitors (CPIs) increase antitumor activity by unblocking regulators of the immune response. This action can provoke a wide range of immunologic and inflammatory side effects, some of which can be fatal. Recent studies suggest that CPI-induced immune-related adverse events (irAEs) may p...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Lynn M., DeBerg, Hannah A., Vishnu, Prakash, Frankel, Jason K., Manjunath, Adarsh B., Flores, John Paul E., Aboulafia, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844139/
https://www.ncbi.nlm.nih.gov/pubmed/33520695
http://dx.doi.org/10.3389/fonc.2020.570752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844139/
https://www.ncbi.nlm.nih.gov/pubmed/33520695
http://dx.doi.org/10.3389/fonc.2020.570752

Ejemplares similares